|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/30/20 Biolase, Inc 10-K 12/31/19 90:24M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.39M
2: EX-4.9 Instrument Defining the Rights of Security Holders HTML 52K
3: EX-10.12 Material Contract HTML 428K
4: EX-10.13 Material Contract HTML 220K
5: EX-10.29 Material Contract HTML 58K
6: EX-21.1 Subsidiaries List HTML 24K
7: EX-23.1 Consent of Experts or Counsel HTML 28K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 34K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
57: R1 Document and Entity Information HTML 89K
27: R2 Consolidated Balance Sheets HTML 120K
37: R3 Consolidated Balance Sheets (Parenthetical) HTML 52K
85: R4 Consolidated Statements Of Operations And HTML 109K
Comprehensive Loss
58: R5 Consolidated Statements Of Redeemable Preferred HTML 115K
Stock And Shareholders' Equity
29: R6 Consolidated Statements Of Redeemable Preferred HTML 26K
Stock And Shareholders' Equity (Parenthetical)
38: R7 Consolidated Statements Of Cash Flows HTML 149K
84: R8 Basis of Presentation HTML 51K
59: R9 Summary of Significant Accounting Policies HTML 276K
51: R10 Supplementary Balance Sheet Information HTML 140K
22: R11 Intangible Assets and Goodwill HTML 68K
72: R12 Income Taxes HTML 241K
80: R13 Debt HTML 106K
50: R14 Commitments and Contingencies HTML 93K
21: R15 Redeemable Preferred Stock and Stockholders' HTML 410K
Equity
71: R16 Segment Information HTML 51K
79: R17 Concentrations HTML 91K
49: R18 Subsequent Events HTML 34K
23: R19 Schedule II-Consolidated Valuation and Qualifying HTML 119K
Accounts and Reserves
55: R20 Summary of Significant Accounting Policies HTML 372K
(Policies)
83: R21 Summary of Significant Accounting Policies HTML 246K
(Tables)
40: R22 Supplementary Balance Sheet Information (Tables) HTML 146K
31: R23 Intangible Assets and Goodwill (Tables) HTML 65K
54: R24 Income Taxes (Tables) HTML 241K
82: R25 Debt (Tables) HTML 76K
39: R26 Commitments and Contingencies (Tables) HTML 79K
30: R27 Redeemable Preferred Stock and Stockholders' HTML 334K
Equity (Tables)
56: R28 Segment Information (Tables) HTML 48K
81: R29 Concentrations (Tables) HTML 91K
76: R30 Basis of Presentation - Additional Information HTML 133K
(Detail)
69: R31 Summary of Significant Accounting Policies - HTML 130K
Additional Information (Detail)
24: R32 Schedule of Reconciliation of Cash, Cash HTML 38K
Equivalents, and Restricted Cash (Detail)
52: R33 Estimated Useful Lives of Property, Plant and HTML 39K
Equipment (Detail)
77: R34 Summary of Opening and Closing Balances of HTML 40K
Contract Liabilities (Detail)
70: R35 Summary of Disaggregation of Revenues Related to HTML 33K
Geographic Areas (Detail)
25: R36 Summary of Revenues Disaggregated by Timing of HTML 34K
Goods and Services Transferred (Detail)
53: R37 Summary of Sales by End Market (Detail) HTML 34K
78: R38 Changes in Initial Product Warranty Accrual and HTML 42K
Expenses Under Initial and Extended Warranties
(Detail)
68: R39 Classification of Compensation Expense Associated HTML 39K
with Share-Based Payments (Detail)
88: R40 Assumptions Used in Estimating Fair Value of Stock HTML 35K
Options Granted (Detail)
63: R41 Components of Accounts Receivable, Net of HTML 36K
Allowance (Detail)
32: R42 Supplementary Balance Sheet Information - HTML 44K
Additional Information (Detail)
41: R43 Components of Inventory (Detail) HTML 36K
89: R44 Summary of Property, Plant, and Equipment (Detail) HTML 51K
64: R45 Components of Accrued Liabilities (Detail) HTML 51K
33: R46 Intangible Assets and Goodwill - Additional HTML 34K
Information (Detail)
42: R47 Intangible Assets and Related Accumulated HTML 53K
Amortization (Detail)
90: R48 Summary of Income Tax Current and Deferred HTML 48K
Provision (Detail)
62: R49 Federal Income Tax Provision Compared With HTML 55K
Statutory Rates (Detail)
66: R50 Summary of Net Deferred Tax Assets and Net HTML 85K
Deferred Tax Liabilities (Detail)
75: R51 Income Taxes - Additional Information (Detail) HTML 52K
47: R52 Summary of Unrecognized Tax Benefits (Detail) HTML 33K
19: R53 Debt - Summary of Principal Outstanding and HTML 36K
Unamortized Discount (Detail)
65: R54 Debt - Additional Information (Detail) HTML 299K
74: R55 Debt - Summary of Future Minimum Principal HTML 48K
Payments (Detail)
46: R56 Commitments and Contingencies - Additional HTML 128K
Information (Detail)
18: R57 Commitments and Contingencies - Information HTML 36K
related to Right-of-use Assets and Liabilities
(Detail)
67: R58 Future Minimum Rental Commitments Under Lease HTML 53K
Agreements (Detail)
73: R59 Redeemable Preferred Stock and Stockholders' HTML 858K
Equity - Additional Information (Detail)
45: R60 Summary of Warrant Activity (Detail) HTML 56K
35: R61 Summary of Option Activity (Detail) HTML 60K
61: R62 Options Outstanding and Exercisable (Detail) HTML 68K
87: R63 Cash Proceeds Along with Fair Value Disclosures HTML 37K
Related to Grants, Exercises, and Vesting Options
(Detail)
44: R64 Summary of Unvested Restricted Stock Units HTML 39K
(Detail)
34: R65 Segment Information - Additional Information HTML 40K
(Detail)
60: R66 Summary of Long-Lived Assets by Geographic HTML 34K
Location (Detail)
86: R67 Concentrations - Summary of Net Revenue from HTML 53K
Various Products (Detail)
43: R68 Concentrations - Additional Information (Detail) HTML 36K
36: R69 Subsequent Events - Additional Information HTML 51K
(Detail)
20: R70 Consolidated Valuation and Qualifying Accounts and HTML 40K
Reserves (Detail)
26: XML IDEA XML File -- Filing Summary XML 156K
48: EXCEL IDEA Workbook of Financial Reports XLSX 123K
12: EX-101.INS XBRL Instance -- biol-20191231 XML 4.34M
14: EX-101.CAL XBRL Calculations -- biol-20191231_cal XML 254K
15: EX-101.DEF XBRL Definitions -- biol-20191231_def XML 884K
16: EX-101.LAB XBRL Labels -- biol-20191231_lab XML 2.06M
17: EX-101.PRE XBRL Presentations -- biol-20191231_pre XML 1.49M
13: EX-101.SCH XBRL Schema -- biol-20191231 XSD 294K
28: ZIP XBRL Zipped Folder -- 0001564590-20-013794-xbrl Zip 279K
Exhibit 32.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. § 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of BIOLASE, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019, (the “Report”), I, Todd A. Norbe, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(i) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 27, 2020 |
|
By:/s/ todd a. norbe |
|
|
|
Todd A. Norbe |
|
|
|
President and Chief Executive Officer (Principal Executive Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/30/20 | |||
| 3/27/20 | ||||
| For Period end: | 12/31/19 | SD | ||
| List all Filings | ||||